| Literature DB >> 28630859 |
Wenlong Zhong1, Yicong Du1, Lei Zhang1, Xuesong Li1, Cuijian Zhang1, Dong Fang1, Gengyan Xiong1, Zhisong He1, Liqun Zhou1.
Abstract
OBJECTIVE: To evaluate the feasibility of an internal suspension technique in retroperitoneal laparoscopic partial nephrectomy for the management of renal ventral tumors.Entities:
Mesh:
Year: 2017 PMID: 28630859 PMCID: PMC5467276 DOI: 10.1155/2017/1849649
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1The application range of the new technique. (a) Single renal exophytic tumors located in ventral side with different sizes (<7 cm). ((b) and (c)) The yellow color on the kidney represents the area of the tumor location for the technique.
Figure 2Schematic diagram of the novel technique in RLPN for renal ventral tumors. (a) The perinephric fat along the surface of the kidney was carefully separated without resecting the perinephric fat atop the tumors. (b) The retained perinephric fat exerted traction on the tumor during tumor resection. (c) The closure of blood vessels and collecting system was performed with a unidirectional barbed suture. (d) The second layer suture was performed to close the parenchyma with the same suture.
Clinical and pathological characteristics of patients with and without natural suspension technique.
| Natural suspension group | Control group |
| |
|---|---|---|---|
| Age (years), mean ± SD | 60.7 ± 9.7 | 62.8 ± 9.2 | .23 |
| Gender, | 1.00 | ||
| Male | 18 (56.3) | 18 (56.3) | |
| Female | 14 (43.7) | 14 (43.7) | |
| Tumor laterality, | .45 | ||
| Right | 15 (46.9) | 18 (56.3) | |
| Left | 17 (53.1) | 14 (43.7) | |
| Tumor location (ventral side), | 32 (100) | 32 (100) | 1.00 |
| BMI (kg/m2), mean ± SD | 22.3 ± 2.6 | 22.3 ± 2.9 | .89 |
| Tumor size (cm), mean ± SD | 2.6 ± 0.97 | 2.6 ± 1.03 | .70 |
| ASA score median (IQR) | 2.0 (1.0–2.0) | 2.0 (1.0–3.0) | .20 |
| RENAL score median (IQR) | 6.0 (5.0–6.8) | 6.0 (5.0–7.0) | .90 |
| Preoperative eGFR (mL/min/1.73 m2), mean ± SD | 84.1 ± 11.6 | 81.9 ± 11.1 | .53 |
| Pathological outcomes | |||
| Histology, | .43 | ||
| Clear cell | 29 (90.6) | 28 (87.5) | |
| Papillary | 2 (6.3) | 4 (12.5) | |
| Chrome | 1 (3.1) | 0 | |
| TNM stage, | 1.00 | ||
| T1aN0M0 | 29 (90.6) | 29 (90.6) | |
| T1bN0M0 | 3 (9.4) | 3 (9.4) | |
| Fuhrman (clear cell), | .49 | ||
| G1 | 6 (20.7) | 9 (32.1) | |
| G2 | 16 (55.2) | 15 (53.6) | |
| G3 | 7 (24.1) | 4 (14.3) |
ASA: American Society of Anesthesiologists; eGFR: estimated Glomerular Filtration Rate; IQR: interquartile range; SD: standard deviation.
Perioperative, oncologic, and functional outcomes of patients with and without natural suspension technique.
| Internal suspension group | Control group |
| |
|---|---|---|---|
| Operative time (min), median (IQR) | 78.5 (68.3–91.3) | 89.0 (78.3–102.3) | .12 |
| WIT (min), median (IQR) | 15.0 (12.3–17.8) | 19.0 (15.0–25.0) | .002 |
| WIT >25 minutes, | 2 (6.3) | 8 (25.0) | .04 |
| Tumor resection time (min), median (IQR) | 4.0 (3.0–6.8) | 7.5 (5.0–11.0) | <.001 |
| EBL (ml), median (IQR) | 53.5 (25.3–70.8) | 50.0 (20.0–70.0) | .21 |
| Positive surgical margins, | 0 (0) | 2 (6.3) | .15 |
| Postoperative complications, | 2 (6.3) | 4 (12.5) | .39 |
| Follow-up time (months), median (IQR) | 21.5 (14.5–29.5) | 21.0 (13.5–25.0) | .58 |
| Trifecta accomplishment, | 28 (87.5) | 20 (62.5) | .02 |
| Postoperative eGFR (mL/min/1.73 m2), mean ± SD | 77.8 ± 10.1 | 74.5 ± 7.9 | .70 |
Statistically significant. WIT: warm ischemia time; EBL: estimated blood loss; eGFR: estimated Glomerular Filtration Rate; IQR: interquartile range; SD: standard deviation.